Search research articles
Contact Us
Filters
Showing results (371-380 of 626) with videos related to
Page
of 63
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 15, 2018
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis
Keith Bowering, Helena W Rodbard, David Russell-Jones, et al.
Fertility and Sterility
|
June 9, 2006
Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis
Cleophas M Kyama, Lutgart Overbergh, Sophie Debrock, et al.
Lancet (London, England)
|
October 20, 2023
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
David Russell-Jones, Tetsuya Babazono, Roman Cailleteau, et al.
Acta Clinica Belgica
|
May 5, 2016
Long-term effects of gastric bypass surgery on psychosocial well-being and eating behavior: not all that glitters is gold
Roman Vangoitsenhoven, Pascal Frederiks, Brecht Gijbels, et al.
Diabetologia
|
February 28, 2025
Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes affirms markers of disease
Robert Moulder, M Karoliina Hirvonen, Tommi Välikangas, et al.
Immunology Letters
|
July 6, 2010
Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile
Lien De Somer, Sabine Fevery, Dominique M A Bullens, et al.
Lancet (London, England)
|
March 15, 2011
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
Bernard Zinman, Greg Fulcher, Paturi V Rao, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|
May 14, 2013
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
Claes-Göran Ostenson, Stephan Matthaei, Matthew Reaney, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
July 23, 2013
Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
Urpo Kiiskinen, Stephan Matthaei, Matthew Reaney, et al.
Cell Death & Disease
|
April 7, 2019
Cytokine-induced translocation of GRP78 to the plasma membrane triggers a pro-apoptotic feedback loop in pancreatic beta cells
Saurabh Vig, Mijke Buitinga, Dieter Rondas, et al.
Page
of 63
Search research articles
Search
Showing results (371-380 of 626) with videos related to
Sort By:
Page
of 63
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 15, 2018
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis
Keith Bowering, Helena W Rodbard, David Russell-Jones, et al.
Fertility and Sterility
|
June 9, 2006
Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis
Cleophas M Kyama, Lutgart Overbergh, Sophie Debrock, et al.
Lancet (London, England)
|
October 20, 2023
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
David Russell-Jones, Tetsuya Babazono, Roman Cailleteau, et al.
Acta Clinica Belgica
|
May 5, 2016
Long-term effects of gastric bypass surgery on psychosocial well-being and eating behavior: not all that glitters is gold
Roman Vangoitsenhoven, Pascal Frederiks, Brecht Gijbels, et al.
Diabetologia
|
February 28, 2025
Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes affirms markers of disease
Robert Moulder, M Karoliina Hirvonen, Tommi Välikangas, et al.
Immunology Letters
|
July 6, 2010
Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile
Lien De Somer, Sabine Fevery, Dominique M A Bullens, et al.
Lancet (London, England)
|
March 15, 2011
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
Bernard Zinman, Greg Fulcher, Paturi V Rao, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|
May 14, 2013
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
Claes-Göran Ostenson, Stephan Matthaei, Matthew Reaney, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
July 23, 2013
Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
Urpo Kiiskinen, Stephan Matthaei, Matthew Reaney, et al.
Cell Death & Disease
|
April 7, 2019
Cytokine-induced translocation of GRP78 to the plasma membrane triggers a pro-apoptotic feedback loop in pancreatic beta cells
Saurabh Vig, Mijke Buitinga, Dieter Rondas, et al.
Page
of 63